Table 4.
Differences in IL-1β levels by COPD disease severity after stimulation of whole blood by PAMPs
| PAMP | COPD severity
|
P-value* | |||
|---|---|---|---|---|---|
| FEV1 <50 (N=16)
|
FEV1 50–80 (N=12)
|
||||
| Median | IQR | Median | IQR | ||
| Media | 1.4 | (1.1–2.1) | 1.1 | (0.9–3.6) | 0.5 |
| Pam3Cys (10 ng/mL) | 56.7 | (32.9–85.4) | 99.4 | (68.4–171.0) | 0.02 |
| Pam3Cys (100 ng/mL) | 68.9 | (35.1–150.5) | 157.6 | (90.8–331.8) | 0.02 |
| Zymosan (10 μg/mL) | 54.4 | (20.6–122.0) | 145.0 | (70.7–178.9) | 0.005 |
| Zymosan (100 μg/mL) | 1,048.3 | (593.9–2,114.1) | 1,717.0 | (1,516.2–2,261.6) | 0.1 |
| FSL-1 (10 ng/mL) | 8.4 | (3.0–20.8) | 15.3 | (4.2–39.3) | 0.3 |
| FSL-1 (100 ng/mL) | 15.1 | (6.8–27.5) | 23.4 | (10.5–59.4) | 0.1 |
| O111:B4 (0.1 ng/mL) | 39.4 | (9.9–97.66) | 41.6 | (18.5–204.1) | 0.2 |
| O111:B4 (1 ng/mL) | 644.2 | (187.3–2,218.1) | 1,112.9 | (983.8–2,335.1) | 0.2 |
| O111:B4 (10 ng/mL) | 1,899.4 | (1,214.7–6,574.6) | 3,989.2 | (2,526.2–6,145.9) | 0.2 |
| Re595UP (0.01 ng/mL) | 126.4 | (39.6–202.4) | 252.2 | (106.7–499.1) | 0.02 |
| Re595UP (0.1 ng/mL) | 1,630.2 | (596.1–2,555.2) | 2,375.7 | (2,171.4–4,362.5) | 0.06 |
| Re595UP (1 ng/mL) | 5,139.8 | (3,230.8–10,174.4) | 8,745.4 | (5,673.4–10,901.3) | 0.2 |
| Flagellin (100 ng/mL) | 3.0 | (1.1–17.8) | 2.1 | (1.5–19.4) | 0.8 |
| R848 (0.1 μM) | 18.0 | (8.5–33.8) | 31.9 | (11.8–59.9) | 0.3 |
| R848 (1 μM) | 5,685.6 | (3,641.2–7,468.2) | 5,204.5 | (4,169.0–8,544.3) | 0.9 |
Note:
*
Wilcoxon rank sum test (Mann–Whitney).
Abbreviations: IL, interleukin; PAMP, pathogen-associated molecular pattern; IQR, inter-quartile range; G-CSF, granulocyte-colony stimulating factor.